Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Cell Cycle (Georgetown, Tex.)|April 23, 2005
Met activation and receptor dimerization in cancer: a role for the Sema domainDineli Wickramasinghe, Monica Kong-BeltranCancer Cell|July 21, 2004
The Sema domain of Met is necessary for receptor dimerization and activationMonica Kong-Beltran, Jennifer Stamos, Dineli WickramasingheMolecular Biology of the Cell|September 16, 2003
Spy1 interacts with p27Kip1 to allow G1/S progressionLisa A Porter, Monica Kong-Beltran, Daniel J DonoghueCell Cycle (Georgetown, Tex.)|September 9, 2011
The tumor suppressor tuberin regulates mitotic onset through the cellular localization of cyclin B1Elizabeth Fidalgo da Silva, Shora B Ansari, Jiamila Maimaiti, et al.ACS Chemical Biology|January 22, 2020
Design of Organo-Peptides As Bipartite PCSK9 AntagonistsDaniel J Burdick, Nicholas J Skelton, Mark Ultsch, et al.The Journal of Biological Chemistry|November 15, 2013
Identification of a small peptide that inhibits PCSK9 protein binding to the low density lipoprotein receptorYingnan Zhang, Charles Eigenbrot, Lijuan Zhou, et al.Journal of Molecular Biology|June 26, 2012
Calcium-independent inhibition of PCSK9 by affinity-improved variants of the LDL receptor EGF(A) domainYingnan Zhang, Lijuan Zhou, Monica Kong-Beltran, et al.Cancer Research|January 7, 2006
Somatic mutations lead to an oncogenic deletion of met in lung cancerMonica Kong-Beltran, Somasekar Seshagiri, Jiping Zha, et al.The Journal of Biological Chemistry|November 9, 2012
Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates low density lipoprotein receptor and serum cholesterol levelsMichael T Lipari, Wei Li, Paul Moran, et al.Nature Structural & Molecular Biology|August 22, 2017
Discovery of a cryptic peptide-binding site on PCSK9 and design of antagonistsYingnan Zhang, Mark Ultsch, Nicholas J Skelton, et al.Pageof 2